As Nektar Therapeutics (NKTR) Stock Value Rose, First Light Asset Management LLC Lowered Holding

April 26, 2018 - By Stephen Andrade

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.19 in 2017 Q4. Its down 0.21, from 1.4 in 2017Q3. It is negative, as 18 investors sold NKTR shares while 82 reduced holdings. 65 funds opened positions while 54 raised stakes. 150.36 million shares or 1.08% more from 148.76 million shares in 2017Q3 were reported. Advisory Service Networks Lc reported 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Redmile Grp Inc Ltd Llc stated it has 5,327 shares. Wellington Mgmt Gru Llp accumulated 2.02M shares. Crow Point Partners Ltd Company stated it has 539 shares or 0.01% of all its holdings. Franklin Street Inc Nc owns 0.52% invested in Nektar Therapeutics (NASDAQ:NKTR) for 58,000 shares. Columbus Circle Investors invested 0.27% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Qs Invsts has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). 1.41 million are owned by Principal Inc. Credit Suisse Ag, a Switzerland-based fund reported 337,785 shares. Los Angeles Capital Management Equity Incorporated holds 0.01% or 39,070 shares in its portfolio. Pub Sector Pension Inv Board, Quebec – Canada-based fund reported 99,255 shares. 264,668 are owned by Arizona State Retirement Systems. Macquarie Gru holds 32,946 shares or 0% of its portfolio. Metropolitan Life Insurance owns 45,958 shares for 0.04% of their portfolio. Blackrock holds 0.06% or 21.43M shares in its portfolio.

Since December 13, 2017, it had 0 buys, and 18 insider sales for $68.39 million activity. On Friday, February 16 Doberstein Stephen K sold $201,212 worth of Nektar Therapeutics (NASDAQ:NKTR) or 2,426 shares. Shares for $404,664 were sold by Nicholson John. Shares for $3.90M were sold by KUEBLER CHRISTOPHER A. ROBIN HOWARD W sold $6.32M worth of Nektar Therapeutics (NASDAQ:NKTR) on Monday, January 22. 25,000 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $2.30M were sold by CHESS ROBERT. Thomsen Jillian B. had sold 2,545 shares worth $211,082 on Friday, February 16.

First Light Asset Management Llc decreased its stake in Nektar Therapeutics (NKTR) by 30.1% based on its latest 2017Q4 regulatory filing with the SEC. First Light Asset Management Llc sold 151,452 shares as the company’s stock rose 80.22% while stock markets declined. The institutional investor held 351,741 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $21.01M, down from 503,193 at the end of the previous reported quarter. First Light Asset Management Llc who had been investing in Nektar Therapeutics for a number of months, seems to be less bullish one the $13.29B market cap company. The stock decreased 2.27% or $1.92 during the last trading session, reaching $82.59. About 2.61M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 26, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

First Light Asset Management Llc, which manages about $154.73M and $364.66M US Long portfolio, upped its stake in Ligand Pharmaceuticals Inc (NASDAQ:LGND) by 48,625 shares to 111,971 shares, valued at $15.33M in 2017Q4, according to the filing.

Analysts await Nektar Therapeutics (NASDAQ:NKTR) to report earnings on May, 8. They expect $-0.43 earnings per share, down 2.38 % or $0.01 from last year’s $-0.42 per share. After $-0.14 actual earnings per share reported by Nektar Therapeutics for the previous quarter, Wall Street now forecasts 207.14 % negative EPS growth.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics has $125 highest and $35.0 lowest target. $91.75’s average target is 11.09% above currents $82.59 stock price. Nektar Therapeutics had 12 analyst reports since November 7, 2017 according to SRatingsIntel. The rating was maintained by Canaccord Genuity on Wednesday, January 10 with “Buy”. The company was initiated on Thursday, November 9 by Canaccord Genuity. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Friday, April 6 by Mizuho. Cowen & Co maintained the stock with “Buy” rating in Monday, April 9 report. The firm earned “Overweight” rating on Friday, April 13 by PiperJaffray. H.C. Wainwright reinitiated Nektar Therapeutics (NASDAQ:NKTR) on Monday, April 2 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Monday, November 13 report. The company was maintained on Wednesday, November 8 by Jefferies. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Thursday, March 29.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.